Sign In
Buy BYSI
$1.74
+0.0400 (+2.35%)
At Close: Jun 03, 2026
BeyondSpring: Would Be A Great Buy Except For The Perennial Need For Cash And Ensuing Dilution
08:00am, Tuesday, 15'th Dec 2020
BYSI's lead candidate plinabulin in combo with Neulasta reduces grade 4 neutropenia in chemo patients better than Neulasta alone.
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
08:00am, Thursday, 10'th Dec 2020
- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone
Do Hedge Funds Love BeyondSpring, Inc. (BYSI)?
09:45am, Sunday, 29'th Nov 2020
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that sm
BeyondSpring to Present at Two Upcoming Scientific Conferences in December
08:59pm, Tuesday, 24'th Nov 2020
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer t
BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference
04:01pm, Monday, 23'rd Nov 2020
NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncol
BeyondSpring Announces Pricing of Ordinary Shares
08:00am, Thursday, 19'th Nov 2020
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative canc
BeyondSpring Announces Proposed Public Offering of Ordinary Shares
04:01pm, Tuesday, 17'th Nov 2020
NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative canc
BeyondSpring Announces Third Quarter 2020 Financial Results and Provides Business Updates
08:00am, Tuesday, 17'th Nov 2020
- Announced SEED Therapeutics Inc.(“SEED”)'s collaboration with Eli Lilly and Company(“Lilly”)
BeyondSpring to Present Corporate Overview at Jefferies London Healthcare Conference
04:46pm, Friday, 13'th Nov 2020
NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncol
BeyondSpring Subsidiary, Seed Therapeutics, Announces Research Collaboration and License Agreement with Lilly
07:00am, Friday, 13'th Nov 2020
- Seed Therapeutics to Use Proprietary “Molecular Glue” Protein Degradation Technology to Develop Potential New Medicines -
BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2020 Results - Earnings Call Transcript
02:29pm, Thursday, 03'rd Sep 2020
BeyondSpring Inc. (NASDAQ:BYSI) Q2 2020 Earnings Conference Call September 3, 2020 8:00 A.M.
Oncology Stocks Area Trading Materially Lower The Last 2 Months
08:00am, Monday, 24'th Aug 2020
Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.
BeyondSpring Appoints Forty Seven, Inc., Co-Founder and Stanford Hematology Veteran, Dr. Ravindra Majeti, to Board of Directors
12:00pm, Tuesday, 18'th Aug 2020
Gilead Acquired Forty Seven in March 2020 for $4.9 BillionNEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceut
BeyondSpring's Plinabulin Offers Multiple Roadmaps (Via Multiple Geographies) To Becoming A Blockbuster
04:43pm, Monday, 17'th Aug 2020
BYSI's Plinabulin, if approved, could out-compete Neulasta (~$5 Billion/Year) to become the new standard of care in chemotherapy.
BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the U.S.
12:00pm, Tuesday, 11'th Aug 2020
\- NCCN Guideline Updates Highlight Need for Maximum CIN Prevention and Resource Allocation for COVID-19 Patients - \- First Patient Dosed in the U.S. Avoided Grade 4 Neutropenia in Cycle 2 with Plin
